The U.S. Food and Drug Administration has approved a new type of twice-daily pill for narcolepsy, marking the first therapy in a drug class that scientists believe could eventually transform treatment for a wide range of sleep and neurological disorders. The medication, developed by Takeda and to be marketed as Orzeyful, is an orexin receptor agonist cleared specifically for narcolepsy type 1, a condition marked by severe daytime sleepiness and sudden muscle weakness.
For patients, the approval addresses a significant unmet need. Existing narcolepsy treatments, including stimulants and sodium oxybates, carry risks of misuse and often leave people still feeling drowsy. In two Phase 3 clinical trials, Orzeyful helped participants stay awake during the day for substantially longer periods than what is typically seen with current options. Across the studies, patients also reported reduced daytime sleepiness, fewer episodes of muscle weakness, and improved attentiveness.
The drug works by activating the brain’s orexin system, which regulates the sleep-wake cycle and promotes alertness. People with narcolepsy type 1 lack orexin-producing neurons, and Orzeyful is designed to replace that missing signal. The most common side effects observed in trials were insomnia, increased urinary frequency and urgency, and increased saliva production. Notably, an earlier orexin pill developed by Takeda was abandoned due to liver toxicity, but Orzeyful has not shown similar concerns in clinical testing.
The approval is seen as a milestone for the entire orexin agonist class. Takeda, along with competitors Alkermes and Eli Lilly, which acquired biotech Centessa, is now testing similar drugs in narcolepsy type 2 and idiopathic hypersomnia, conditions where patients experience excessive sleepiness but do not have the same pronounced orexin deficiency. Because the orexin system also influences cognition and motivation, drugmakers have broader ambitions to study these treatments in neuropsychiatric conditions such as Alzheimer’s disease and depression, where fatigue and sleepiness are common symptoms.
Takeda’s journey to this approval spanned more than a decade, making it the first company to focus on orexin agonists. The company has a U.S. hub in Massachusetts. With the FDA clearance now in hand, the next steps involve launching Orzeyful for patients and continuing to gather long-term safety data. Researchers and patient advocates alike are watching closely, hopeful that this new class of medications could offer relief not just for narcolepsy but for millions of people living with other debilitating sleep and neurological conditions.